Cleveland Danielle
National Institute of Standards and Technology
Gadolinium-based magnetic resonance imaging (MRI) contrast agent (CA) formulations have been routinely applied in the clinical setting to improve differentiation among neighboring tissues of interest. Although the free gadolinium ion has potentially toxic effects , complexation of the ion by various ligands has been shown to improve acute tolerance. Nanoemulsion-based CAs, which use liposomal ligands to chelate the gadolinium, have shown promise as highly potent contrast agents, due to their accommodation of a significantly higher gadolinium payload, improved relaxivities, and reduced incidents of release of gadolinium ions compared to traditional CAs. With the advent of these new types of gadolinium-ligand complexes, it remains crucial to measure the amounts of total, bound, and uncomplexed gadolinium in CA formulations. This technical procedure defines the analytical protocols for gadolinium speciation measurements in liposomal MRI CA formulations that contain emulsifiers, surfactants, and therapeutic agents.
基于钆的磁共振成像(MRI)造影剂(CA)制剂已在临床环境中常规应用,以改善感兴趣的相邻组织之间的区分。尽管游离钆离子具有潜在毒性作用,但已表明该离子与各种配体的络合可提高急性耐受性。基于纳米乳液的造影剂使用脂质体配体螯合钆,由于其能容纳显著更高的钆负载量、改善的弛豫率以及与传统造影剂相比降低了钆离子释放事件,已显示出作为高效造影剂的前景。随着这些新型钆 - 配体络合物的出现,测量造影剂制剂中总钆、结合钆和未络合钆的量仍然至关重要。本技术程序定义了用于含有乳化剂、表面活性剂和治疗剂的脂质体MRI造影剂制剂中钆形态测量的分析方案。